Showing results (31-40 of 64) with videos related to
Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|March 10, 2021
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancerDavide Melisi, Do-Youn Oh, Antoine Hollebecque, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib TrialAmita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.The Lancet. Oncology|August 26, 2014
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studyShirish M Gadgeel, Leena Gandhi, Gregory J Riely, et al.European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I studyLeora Horn, Scott N Gettinger, Michael S Gordon, et al.The Lancet. Oncology|December 29, 2015
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialAlice T Shaw, Leena Gandhi, Shirish Gadgeel, et al.Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene AlterationsMartin H Voss, Cinta Hierro, Rebecca S Heist, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2021
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 AntibodyJames J Harding, Victor Moreno, Yung-Jue Bang, et al.European Journal of Cancer (Oxford, England : 1990)|June 25, 2017
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteriaLeena Gandhi, Sai-Hong Ignatius Ou, Alice T Shaw, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung CancerHossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.Pageof 7